SCHEMBL6500609

SCHEMBL6500609

COCc1cnc(Cn2c(C)nc3c(C)cc(OCc4cccc(C)c4C(=O)OC)cc32)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 7/20 0.38
PIK3C2B O00750 2/20 0.34
KMT2A Q03164 1/20 0.34
THRB P10828 1/20 0.33
HSP90AA1 P07900 1/20 0.32
HSP90B1 P14625 1/20 0.32
MAPT P10636 2/20 0.32
ABL1 P00519 1/20 0.32
SRC P12931 1/20 0.32
TP53 P04637 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
ALOX5AP P20292 1/20 0.32
BCL2 P10415 1/20 0.32
MCL1 Q07820 1/20 0.32
HSD17B13 Q7Z5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492991 0.93 DCTPP1 (0.36) DCTPP1PIK3C2BKMT2ATHRBHSP90AA1
SCHEMBL6503787 0.93 PIK3C2B (0.38) DCTPP1PIK3C2BALOX5APBCL2MCL1
SCHEMBL6499279 0.91 BCL2 (0.38) DCTPP1PIK3C2BKMT2AMAPTTP53
SCHEMBL6488928 0.86 BCL2 (0.44) PIK3C2BTP53BCL2MCL1
SCHEMBL6491725 0.85 PIK3C2B (0.37) DCTPP1PIK3C2BALOX5APBCL2MCL1
SCHEMBL6492258 0.84 ALDH1A1 (0.35) DCTPP1PIK3C2BKMT2ATHRBMAPT
SCHEMBL6490267 0.84 BCL2 (0.38) DCTPP1KMT2ATHRBMAPTTP53
SCHEMBL6495279 0.83 MAPT (0.36) DCTPP1PIK3C2BTHRBMAPTTP53
SCHEMBL6501064 0.83 PIK3C2B (0.38) DCTPP1PIK3C2BKMT2ABCL2MCL1
SCHEMBL6488710 0.81 BCL2 (0.39) DCTPP1MAPTTP53ALDH1A1BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD DCTPP1 1534/4885PIK3C2B 2433/4885KMT2A 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.